Organ allotransplantation is currently limited by chronic rejection and the toxicity of non-specific long-term immunosuppressive therapy, with its increased risks of malignancies and infections. A state of immunological tolerance would obviate the need for chronic immunosuppression and prevent chronic rejection. Mixed hematopoietic chimerism has been shown in animal models to be a reliable means of inducing robust transplantation tolerance. Unfortunately, clinical application of mixed chimerism. for the induction of organ transplant acceptance has been precluded by the toxicity associated with the host conditioning traditionally thought to be necessary to achieve marrow engraftment in adult recipients. We have developed murine and primate models showing that allogeneic bone marrow engraftment can be achieved across MHC barriers, leading to mixed chimerism and tolerance, without the requirement for lethal host conditioning. We have now applied a modification of this approach, involving the induction of mixed chimerism followed by donor leukocyte infusions, to the treatment of humans with advanced hematologic malignancies. These studies have demonstrated for the first time that stable mixed hematopoietic chimerism can be achieved in HLA-mismatched BMT recipients who are conditioned with a relatively non-toxic, non-myeloablative regimen. We have also reliably achieved mixed chimerism in HLA- matched donor-recipient pairs, with minimal GVHD. Several of these transplants have included major and minor ABO mismatches. Preliminary data showing a loss of anti-donor isohemagglutin and the development of mixed erythroid and B cell chimerism suggest that a state of tolerance may be achieved among B cells that produce anti-blood group natural antibodies. If confirmed, this result would be consistent with studies in the murine mixed chimera model showing that natural antibody-producing B cells are rapidly tolerized by the engraftment of donor hematopoietic cells expressing the target antigen. Additional preliminary data are consistent with the presence of a state of T cell tolerance in mixed chimeras. We propose to systematically evaluate the evolution of donor-vs-host (GvH) and host-vs-donor (HvG) T cell tolerance in these mixed chimeras, and to determine its mechanisms. We will also investigate the relationships between B cell chimerism, erythroid chimerism and tolerance of B cell populations that produce anti-donor and anti-host isoagglutinatins in ABO-mismatched BMT recipients. The demonstration of T cell and B cell tolerance in these human mixed chimeras produced with non-myeloablative conditioning would help to determine the potential of this new BMT strategy for the induction of tolerance to organ allografts, and to treat hemoglobinopathies and other non-malignant disorders.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL063474-02
Application #
6139324
Study Section
Special Emphasis Panel (ZRG1-SSS-J (04))
Project Start
1999-01-22
Project End
2003-12-31
Budget Start
2000-01-01
Budget End
2000-12-31
Support Year
2
Fiscal Year
2000
Total Cost
$281,324
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Sykes, Megan (2010) Immune evasion by chimeric trachea. N Engl J Med 362:172-4
Shaffer, Juanita; Villard, Jean; Means, Terry K et al. (2007) Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol 35:1140-52
Fudaba, Y; Spitzer, T R; Shaffer, J et al. (2006) Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 6:2121-33
Rubio, Marie T; Means, Terry K; Chakraverty, Ronjon et al. (2005) Maturation of human monocyte-derived dendritic cells (MoDCs) in the presence of prostaglandin E2 optimizes CD4 and CD8 T cell-mediated responses to protein antigens: role of PGE2 in chemokine and cytokine expression by MoDCs. Int Immunol 17:1561-72
Spitzer, Thomas R; McAfee, Steven L; Dey, Bimalangshu R et al. (2003) Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75:1748-51
Kraus, Annette B; Shaffer, Juanita; Toh, Han Chong et al. (2003) Early host CD8 T-cell recovery and sensitized anti-donor interleukin-2-producing and cytotoxic T-cell responses associated with marrow graft rejection following nonmyeloablative allogeneic bone marrow transplantation. Exp Hematol 31:609-21
Koenecke, Christian; Shaffer, Juanita; Alexander, Stephen I et al. (2003) NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 31:911-23
Sykes, M; Sachs, D H (2001) Mixed chimerism. Philos Trans R Soc Lond B Biol Sci 356:707-26